



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN: L74899DL1978PLC009181

JPL/SEC/RESU-NOT1

Date : November 14th, 2014

The National Stock Exchange of India Limited
Kind Attn: Mr. Hari K. - Vice President
Exchange Plaza, Bandra-Kurla Complex
Bandra E), Mumbai - 400 051.
FAX 022-26598237-38

The Bombay Stock Exchange Limited
Pherozebhoy Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
FAX 022-22723121, 22722037, 22723719, 22722041

**SUB: UN-AUDITED FINANCIAL RESULTS FOR QUARTER/YEAR ENDED 30.09.2014
& AUDITOR'S REPORT ON FINANCIAL RESULTS. (LIMITED REVIEW)**

Dear Sir,

In terms of Clause 41 of the listing agreement we are sending herewith un-audited financial results for the quarter/year ended 30th september, 2014 and Auditor's Report on Financial Results..(Limited Review)

Thanking you.

Yours faithfully,
for **JAGSONPAL PHARMACEUTICALS LIMITED**



R K KAPOOR
COMPLIANCE OFFICER CUM COMPANY SECRETARY



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN No:- L74899DL1978PLC009181

Unaudited Financial Results for the Quarter / Half year ended 30.09.2014

Particulars	3 months ended 30.09.2014 Unaudited	3 months ended 30.06.2014 Unaudited	3 months ended 30.09.2013 Unaudited	6 Months ended 30.09.2014 Unaudited	6 Months ended 30.09.2013 Unaudited	12 Months Ended 31.03.2014 Audited
Rs. in lacs						
1 Income from operations						
a Net sales/Income from Operations (Net of excise duty)	3296.06	3391.31	3678.97	6687.37	7486.85	14385.09
b Other Operating Income						
Total Income from operations (net)	3296.06	3391.31	3678.97	6687.37	7486.85	14385.09
2 Expenses						
a Cost of materials consumed	1993.77	861.62	954.13	2855.39	2956.81	5461.64
b Purchases of stock-in-trade	347.08	209.63	276.84	556.71	423.93	1294.90
c Changes in inventories of finished goods, work in progress	-859.78	464.84	553.87	-394.94	520.28	-285.94
d Employee benefits expenses	754.6	894.98	972.98	1649.58	1847.87	3783.43
e Depreciation and amortisation expense	71.81	71.09	71.02	142.90	140.13	282.54
f Other expenses	813.35	670.67	728.71	1484.02	1340.57	3063.27
Total expenses	3120.83	3172.83	3557.55	6293.66	7229.59	13599.84
3 Profit from Operations before Other Income, Finance Cost and Exceptional items (1-2)	175.23	218.48	121.42	393.71	257.26	785.25
4 Other Income	2.03	3.11		5.14	0.00	6.07
5 Profit from ordinary activities before finance cost and Exceptional items (3+4)	177.26	221.59	121.42	398.85	257.26	791.32
6 Finance Cost	107.54	120.61	111.83	228.15	246.81	538.19
7 Profit from ordinary activities after finance cost but before Exceptional Items (5-6)	69.72	100.98	9.59	170.70	10.45	253.13
8 Exceptional Items						
9 Profit/(+)/Loss(-) from Ordinary Activities before tax (7+8)	69.72	100.98	9.59	170.70	10.45	253.13
10 Tax expense	33.00	30.00	9.00	63.00	9.50	41.06
11 Net Profit/Loss(-) from Ordinary Activities after tax (9-10)	36.72	70.98	0.59	107.70	0.95	212.07
12 Extraordinary Items (net of tax expense Rs. lacs)						
13 Net Profit/(+)/Loss(-) for the period(11-12)	36.72	70.98	0.59	107.70	0.95	212.07
14 Share of profit/(Loss) of associates						
15 Minority interest						
16 Net Profit/(Loss) after taxes, minority interest and share of	36.72	70.98	0.59	107.70	0.95	212.07
17 Paid up Ea. Sh. Cap.(Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90	1309.90	1309.90
18 Reserves excluding Revaluation reserves as per Balance sheet of pr. Accounting yr						7298.31
19.i Earnings Per Share (before extraordinary items)						
a. Basic (Rs.)	0.14	0.27	0.00	0.41	0.00	0.81
b. Diluted (Rs.)	0.14	0.27	0.00	0.41	0.00	0.81
19.ii Earnings Per Share (after extraordinary items)						
a. Basic (Rs.)	0.14	0.27	0.00	0.41	0.00	0.81
b. Diluted (Rs.)	0.14	0.27	0.00	0.41	0.00	0.81
A PARTICULARS OF SHAREHOLDING						
1 Public Shareholding						
- Number of shares	8076680	8962360	8962360	8076680	8962360	8962360
- Percentage of Shareholding	30.83%	34.21%	34.21%	30.83%	34.21%	34.21%
2 Promoter and promoter group shareholding						
A Pledged / encumbered						
- Number of shares						
- Percentage of shares (as a % of the total shareholding of Promoter and promoter group)						
- Percentage of shares (as a % of the total share capital of the Company)						
B Non - encumbered						
- Number of shares	18121320	17235640	17235640	18121320	17235640	17235640
- Percentage of shares (as a % of the total shareholding of Promoter and promoter group)	100%	100%	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the Company)	69.17%	65.79%	65.79%	69.17%	65.79%	65.79%
B INVESTOR COMPLAINTS						
Pending at the beginning of the quarter	0					
Received during the quarter	34					
Disposed of during the quarter	34					
Remaining unresolved at the end of the quarter	0					

Notes

- The Unaudited Financial Results for the Quarter / Half Year ended 30.9.2014 have been reviewed by the Audit Committee. The Board of Directors has approved the financial Results at its meeting held on 14.11.2014
- The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
- The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.
- Previous year figures have been regrouped / rearranged wherever necessary.



Place : New Delhi
Date : 14.11.2014

By Order of the Board
For Jagsonpal Pharmaceuticals Limited


Rajpal Singh Kochhar
Managing Director
DIN No 00059492

Factory : 20 K.M. Mathura Road, Post Office Amar Nagar, Faridabad-121003 (India) Phone : 0091-95129-2275952, 2275953
Factory : Plot No. 14, 15, 16, 55, 56, 57, Sector-5, IIE, Pant Nagar, Rudrapur (U.S. Nagar) - 263153 Uttara Khand

Statement of Assets and Liabilities

Rs. In lacs				Rs. In lacs			
A	EQUITY AND LIABILITIES	As at 30.09.2014 Unaudited	As at 31.03.2014 Audited	B	ASSETS	As at 30.09.2014 Unaudited	As at 31.03.2014 Audited
1	Shareholders' funds			1	Non-current assets		
	(a) Share Capital	1309.90	1309.90		(a) Fixed Assets	5770.60	5872.74
	(b) Reserves and surplus	8656.57	8548.97		(b) Goodwill	3.00	3.00
	Sub-total - Shareholders' funds	9966.47	9858.87		(c) Non-current investments	0.05	0.05
					(d) Deferred tax assets (net)	0.00	0.00
2	Share application money pending allotment	0.00	0.00		(e) Long term loans and advance	633.52	618.52
3	Minority interest	0.00	0.00		(f) Other non-current assets	0.00	0.00
					Sub-total - Non-current assets	6407.17	6494.31
4	Non-current liabilities						
	(a) Long term borrowings	0.00	0.00				
	(b) Deferred tax liabilities (net)	378.39	408.39				
	(c) Other long term liabilities	0.00	0.00				
	(d) Long term provisions	0.00	0.00				
	Sub-total - Non-current liabilities	378.39	408.39	2	Current assets		
5	Current liabilities				(a) Current investments		
	(a) Short term borrowing	3593.76	3595.76		(b) Inventories	3460.02	3058.92
	(b) Trade payables	703.11	508.45		(c) Trade receivables	4511.04	4522.09
	(c) Other current liabilities	573.44	548.10		(d) Cash and Cash equivalents	1265.09	1260.42
	(d) Short term provisions	739.15	706.15		(e) Short term loans and advance	311.00	289.98
	Sub-Total - Current liabilities	5609.46	5358.46		(f) Other current assets	0.00	0.00
					Sub-Total - Current assets	9547.15	9131.41
	TOTAL - EQUITY AND LIABILITIES	15954.32	15625.72		TOTAL - ASSETS	15954.32	15625.72

for Jagsonpal Pharmaceuticals Limited



Managing Director

LIMITED REVIEW REPORT FOR JAGSONPAL PHARMACEUTICALS LIMITED

TO WHOM IT MAY CONCERN

We have reviewed the accompanying statement of unaudited financial results of Jagsonpal Pharmaceuticals Limited for the period ended 30.09.2014, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

**for P. P. THUKRAL & CO.,
Chartered Accountants**



Place : New Delhi
Date : 14.11.2014

**SURESH SETHI
PARTNER
F.R. No. 000632 N
Membership no. 89318**